犬尿氨酸通路与双相障碍:单胺能、谷氨酸能系统与免疫反应的交叉点
本研究探讨氯胺酮对双相抑郁患者犬尿氨酸通路的影响及其与炎症和行为指标的关系。基线促炎细胞因子和行为指标可预测氯胺酮后犬尿氨酸通路变化。
要点
- 氯胺酮可降低双相抑郁患者IDO水平并升高KYN和KynA水平。
- 基线促炎细胞因子和行为指标可预测氯胺酮后犬尿氨酸通路变化。
- 氯胺酮可能通过影响犬尿氨酸通路连接免疫、单胺能和谷氨酸能系统。
核心结论
- 氯胺酮在双相抑郁患者中除具有快速持续抗抑郁效应外,还影响犬尿氨酸通路的关键组分。
- 基线促炎细胞因子和行为指标可预测氯胺酮后犬尿氨酸通路的变化。
研究设计与样本
- 在基线(输注前)、230分钟、第1天和第3天检测血浆IDO、KYN、KynA和QA浓度,采用广义线性模型(限制最大似然估计和稳健三明治方差估计)分析。
主要发现
- 控制年龄、性别和BMI后,氯胺酮后IDO水平在三个时间点均显著低于基线。
- 氯胺酮治疗使KYN和KynA水平在第1天和第3天显著高于基线。
- 氯胺酮后QA水平无变化,第1天QA/KYN比值降低。
- 基线促炎细胞因子和行为测量可预测氯胺酮后犬尿氨酸通路变化。
临床怎么用
- 氯胺酮可能通过调节犬尿氨酸通路发挥抗抑郁作用,基线炎症和行为指标或可用于预测治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dysfunction in a wide array of systems-including the immune, monoaminergic, and glutamatergic systems-is implicated in the pathophysiology of depression. One potential intersection point for these three systems is the kynurenine (KYN) pathway. This study explored the impact of the prototypic glutamatergic modulator ketamine on the endogenous KYN pathway in individuals with bipolar depression (BD), as well as the relationship between response to ketamine and depression-related behavioral and peripheral inflammatory markers. Thirty-nine participants with treatment-resistant BD (23 F, ages 18-65) received a single ketamine infusion (0.5 mg/kg) over 40 min. KYN pathway analytes-including plasma concentrations of indoleamine 2,3-dioxygenase (IDO), KYN, kynurenic acid (KynA), and quinolinic acid (QA)-were assessed at baseline (pre-infusion), 230 min, day 1, and day 3 post-ketamine. General linear models with restricted maximum likelihood estimation and robust sandwich variance estimators were implemented. A repeated effect of time was used to model the covariance of the residuals with an unstructured matrix. After controlling for age, sex, and body mass index (BMI), post-ketamine IDO levels were significantly lower than baseline at all three time points. Conversely, ketamine treatment significantly increased KYN and KynA levels at days 1 and 3 versus baseline. No change in QA levels was observed post-ketamine. A lower post-ketamine ratio of QA/KYN was observed at day 1. In addition, baseline levels of proinflammatory cytokines and behavioral measures predicted KYN pathway changes post ketamine. The results suggest that, in addition to having rapid and sustained antidepressant effects in BD participants, ketamine also impacts key components of the KYN pathway.
引用
- Kadriu B, Farmer CA, Yuan P, et al. The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. Mol Psychiatry. 2019. PMID: 31732715. doi:10.1038/s41380-019-0589-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。